Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 19, 2017
Pharmacy Choice - Pharmaceutical News - Patent Issued for Enhanced Stability of Novel Liquid Compositions (USPTO 9744133) - September 19, 2017

Pharmacy News Article

 9/11/17 - Patent Issued for Enhanced Stability of Novel Liquid Compositions (USPTO 9744133)

By a News Reporter-Staff News Editor at Pharma Business Week Pfizer Inc. (New York, NY) has been issued patent number 9744133, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors (see also Pharmaceutical Companies).

The patent's inventors are Agisim, Gary Robert (Henrico, VA); Friedline, Robert Alan (Midlothian, VA); Patel, Shivangi Akash (Mechanicsville, VA); Sertzen, Cesar Ivan (Richmond, VA); Shepperson, Vanessa Rose (Powhatan, VA).

This patent was filed on February 4, 2016 and was published online on August 29, 2017.

From the background information supplied by the inventors, news correspondents obtained the following quote: "Liquid, and especially concentrated liquid, pharmaceutical compositions offer several advantages over solid compositions. Liquids are easy to swallow and provide an excellent vehicle for the uniform delivery of pharmaceutical agents. Moreover, liquids provide a rapid onset of pharmacologic action, since the composition does not first have to disintegrate and dissolve in the gastrointestinal tract. Likewise, concentrated liquid compositions offer certain distinct advantages, such as faster onset of efficacy due to the high concentration of pharmaceutical agents. Consumers prefer a concentrated liquid composition due to the ease of dosing, and less volume of doses.

"These advantages notwithstanding, it is, however, often difficult to prepare such compositions using the desired pharmaceutical agents. Many pharmaceutical agents are poorly soluble and, therefore, require relatively large volumes of solvent for dissolution, resulting in impractically large doses. Furthermore, the situation becomes even more complicated when multiple pharmaceutical agents are involved, and particularly where the soluble pharmaceutical agent is in combination with additional water soluble pharmaceutical agent(s) that may hinder the efficacy of at least one or more of the pharmaceutical agents and produce a bitter taste that consumers would be discouraged from using.

"Guaifenesin is a well known pharmaceutical agent, classified as an expectorant, and is sold as tablets or syrups under many brand names. Single-ingredient formulations of guaifenesin are available, and it is also included in many other over-the-counter cough and cold remedy combinations, usually in conjunction with dextromethorphan and/or acetominophen and/or ephedrine/pseudoephedrine or phenylephrine. Guaifenesin is a component of Robitussin.TM. DM, Robitussin.TM. DM MAX, Robitussin.TM. CF Max and other well known brand names. Generally the concentration of guaifenesin in most over-the-counter cough medicines is approximately 100 mg/5 mL liquid to 200 mg/5 mL. As an example, the Robitussin.TM. CF Max product contains 100 mg/5 mL and Mucinex.TM. Fast-Max.TM. Severe Congestion and Cough product contains 100 mg guaifenesin/5 mL liquid.

"It has been reported in the literature that the aqueous solubility of guaifenesin, a soluble drug in water, could be significantly reduced in the presence of salts, sugars, and higher concentrations of cosolvents. See 'Solubility of Guaifenesin In The Presence Of Common Pharmaceutical Additives,' Narasimhan Mani, Pharm Dev Technol 8:385-96. 2003.

"Many commercially available over-the-counter liquid cold, cough, flu, fever, and/or allergy preparations contain pseudoephedrine as an active agent. Although such preparations have been useful, misuse of such products as a starting material for synthesis of illicit substances has lead to the desire to find alternatives that are not suitable for such illicit synthesis. Phenylephrine is a potential alternative agent. However, phenylephrine is susceptible to degradation. The degradation is typically facilitated in excipient compositions of the type typically used with pseudoephedrine.

"Accordingly, it would be desirable to have a palatable, stable, liquid composition with inhibited precipitation of pharmaceutical agents, such as guaifenesin, alone or in combination with additional pharmaceutical agents, such as phenylephrine, in a mixture of polyethylene glycol, polyvinylpyrrolidone and propylene glycol."

Supplementing the background information on this patent, NewsRx reporters also obtained the inventors' summary information for this patent: "In one embodiment, the present invention relates to an oral liquid composition comprising: i.) from about 0.1% to about 20% w/v polyvinylpyrrolidone; ii.) from about 5% to about 70% w/v polyethylene glycol; iii.) from about 1% to about 30% w/v propylene glycol; iv.) from about 1% to 10% w/v guaifenesin; and v.) from about 0.01% to about 1.0% w/v phenylephrine.

"In another embodiment, the present invention relates to a liquid oral pharmaceutical composition comprising: i.) about 0.2% w/v dextromethorphan; ii.) about 4% w/v guaifenesin; iii.) about 0.1% w/v phenylephrine; iv.) about 10% w/v propylene glycol; v.) about 10% w/v polyethylene glycol; and vi.) about 0.5% w/v polyvinylpyrrolidone.

"The composition may be a solution or a suspension. In some embodiments the composition may be filled into capsules.

"The present invention further relates to a process for preparing an oral liquid composition, comprising the steps of: a.) mixing until dissolved from about 0.1% to about 20% w/v of polyvinylpyrrolidone in an aqueous phase; b.) adding and mixing from about 1% to about 20% w/v of at least one pharmaceutical agent; c.) subsequently adding and mixing: i.) water; ii.) from about 1% to about 30% w/v of a propylene glycol; iii.) from about 5% to about 70% w/v of a polyethylene glycol; and d.) subsequently adding and mixing one or more additional ingredients."

For the URL and additional information on this patent, see: Agisim, Gary Robert; Friedline, Robert Alan; Patel, Shivangi Akash; Sertzen, Cesar Ivan; Shepperson, Vanessa Rose. Enhanced Stability of Novel Liquid Compositions. U.S. Patent Number 9744133, filed February 4, 2016, and published online on August 29, 2017. Patent URL: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9744133.PN.&OS=PN/9744133RS=PN/9744133

Keywords for this news article include: Pharmaceutical Companies, Alkenes, Guaiacol, Polyenes, Mydriatics, Polyvinyls, Guaifenesin, Pfizer Inc., Hydrocarbons, Vasopressors, Ethanolamines, Phenylephrine, Vinyl Compounds, Propylene Glycol, Organic Chemicals, Drugs and Therapies, Polyethylene Glycols, Cardiovascular Agents, Anorectal Preparations.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC



(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Sep 19: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Last Chance
Sep 20: What's New? New Treatments for Type 2 Diabetes
Sep 21: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Sep 22: Influenza 2017-2018: An Update on Prevention and Treatment
Sep 24: Using Effective Communication to Reduce Medication Errors
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415